RxDoctor Payments Data

Bikram Sekhon

Nephrology · Lakewood, CANPI 1891039871

Payments from drug & device makers

$850in general payments, 2019–2025

Across 28 payments — averaging $30.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aurinia Pharma U.S., Inc.$172
  • Bayer$145
  • Baxter Healthcare$109
  • Vifor Pharma, Inc.$90
  • AstraZeneca$82
  • Fresenius USA Marketing, Inc.$75
  • plus $178 from 5 others

What the payments were for

  • Food & beverage$83098%
  • Education$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$850 in reported general payments places this provider in the 40th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$320,789
Medicare patients
397
Services billed
1,774

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol190$173,267
Sevelamer Hcl35$75,228
LokelmaSodium Zirconium Cyclosilicate86$73,909
VelphoroSucroferric Oxyhydroxide21$57,690
JardianceEmpagliflozin45$48,137
VeltassaPatiromer Calcium Sorbitex30$45,940
Sevelamer Carbonate91$28,744
ProcritEpoetin Alfa20$22,187
DapagliflozinDapagliflozin Propanediol29$21,610
Cinacalcet Hcl41$13,728
ProsolParenteral Amino Acid 20% No.141$5,378
Midodrine Hcl25$4,522
Calcium Acetate36$2,351
Losartan Potassium145$2,029
Amlodipine Besylate256$1,719

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$82$247,176276 claims
Fresenius USA Marketing, Inc.Velphoro$75$57,69021 claims
Boehringer IngelheimJardiance$53$48,13745 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,341 nephrology providers in California.

Other nephrology in Lakewood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →